Literature DB >> 22331075

[Intravesical therapy of non-muscle invasive bladder tumors].

F Vom Dorp1, S Tschirdewahn, G Lümmen.   

Abstract

Intravesical therapy of non-muscle invasive bladder tumors has a long tradition. With regard to low grade tumors prevention of tumor recurrence remains the main endpoint, whereas in high grade tumors prevention of tumor progression is the main aim of intravesical treatment. The following article critically discusses these aspects of non-muscle invasive bladder tumors.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22331075     DOI： 10.1007/s00120-011-2775-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  14 in total

Review 1.  The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; J Alfred Witjes
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

2.  Is maintenance Bacillus Calmette-Guérin really necessary?

Authors:  Harry W Herr
Journal:  Eur Urol       Date:  2008-06-25       Impact factor: 20.096

3.  A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.

Authors:  K Okamura; T Kinukawa; Y Tsumura; T Otani; H Itoh; H Kobayashi; O Matsuura; M Kobayashi; T Fukatsu; S Ohshima
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

4.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

5.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.

Authors:  C Bouffioux; K H Kurth; A Bono; W Oosterlinck; C B Kruger; M De Pauw; R Sylvester
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

6.  [Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].

Authors:  J Hess; S Tschirdewahn; T Szarvas; R Rossi; H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

7.  Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?

Authors:  H W Herr
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

8.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

9.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; Adrian P M van der Meijden
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  [Urine-based cytological diagnosis against the background of the new histopathological classification].

Authors:  S Tschirdewahn; C Boergermann; M Becker; T Szarvas; H Rübben; F vom Dorp
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639
View more
  2 in total

1.  [Visual diagnosis while performing transurethral resection of bladder tumors: power or myth?].

Authors:  S Steffens; A J Schrader; R Lehmann; H Eggers; S Ising; D Pfister; N Riechert-Mühe; A Leitenberger; A Heidenreich; W Thon; A S Merseburger; M A Kuczyk
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

2.  [Secondary prevention in patients with superficial urothelial carcinoma].

Authors:  T J Schnöller; F Zengerling; C Hirning; F Jentzmik
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.